Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 8/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | F12 | P00748 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18637144 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2DPP4DPP7POLBNPSR1 | |
| SCHEMBL26523380 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2DPP4DPP7POLBNPSR1 | |
| SCHEMBL17087644 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2DPP4DPP7POLBNPSR1 | |
| SCHEMBL23658147 | 0.84 | DPP4 (0.34) | DPP4DPP7F2F9F10 | |
| SCHEMBL19302838 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2PREPF2RAB9A | |
| SCHEMBL17087646 | 0.75 | CNR1 (0.32) | L3MBTL1CHRM5CHRM3 | |
| SCHEMBL17789313 | 0.74 | CHRM5 (0.32) | CHRM5CHRM3 | |
| SCHEMBL14558067 | 0.72 | CHRM5 (0.31) | CHRM5CHRM3 | |
| SCHEMBL14574265 | 0.72 | CHRM5 (0.31) | CHRM5CHRM3 | |
| SCHEMBL21335271 | 0.72 | NRP1 (0.38) | SMN1; SMN2DPP4DPP7F2F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | SMN1; SMN2 4565/4885DPP4 942/4885DPP7 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.